Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health ca…
$86.05+0.87%
报价 2026-11-06
市值
$9.59B
EV
$13.24B
PE (TTM)
24.9x
预期 PE (FY2026)
15.7x
52 周区间距高点 -5.3%
$68.99$90.86
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 5.30 → 6.00（1.1x） | 14.3 |
| FY+32028-12 | 1.1x | 5.30 → 6.59（1.2x） | 13.1 |
毛利率 30% · TTM 收入 $13734M · 基数 EPS 5.30（调整后）
电话会信号
辅助标签Q3 20262026-11-03
需求加速积压订单词频高上调指引
指引 上调
信心 5
分析师 4
“We expect to deliver double-digit earnings growth in 2027 and beyond, driven by value creation and share gains.”
原文引用（2）
- 需求加速：US dental merchandise sales grew 8.6% with local currency internal sales growth of 7%, as growth continued to accelerate.
- 上调指引：We now expect 2026 non GAAP diluted EPS attributable to Henry Schein, Inc. to be in the range of $5.50 to $5.56. Compared to prior guidance of $5.29 to $5.39.
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| HSICHenry Schein, Inc. | $9.59B | +0.9% | +5.8% | 31.8% | 24.9x | 12.7x | 17.8x | |
| DVADaVita Inc. | $12.04B | -1.8% | +4.8% | 30.9% | 17.5x | 9.3x | 11.8x | |
| HALOHalozyme Therapeutics, Inc. | $11.76B | -15.7% | +27.0% | 78.2% | 29.3x | 20.9x | 15.2x | |
| MOHMolina Healthcare, Inc. | $10.91B | -3.5% | -0.6% | 8.2% | – | 31.2x | 45.8x | |
| AVTRAvantor, Inc. | $10.48B | +2.2% | +2.2% | 31.5% | 30.9x | 15.1x | 23.9x | |
| BIOBio-Rad Laboratories, Inc. | $10.25B | +3.4% | +0.1% | 51.9% | 9.4x | 9.6x | 27.2x | |
| GMEDGlobus Medical, Inc. | $9.54B | -12.8% | +9.9% | 67.4% | 21.9x | 13.9x | 16.5x | |
| ATRAptarGroup, Inc. | $9.03B | -1.1% | +8.7% | 27.8% | 22.0x | 11.1x | 25.3x | |
| GRFSGrifols, S.A. | $7.13B | -0.4% | – | 38.4% | 15.2x | 10.0x | – | |
| 同行中位数 | – | – | +4.8% | 34.9% | 21.9x | 12.5x | 23.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-27 Q2 2026 | 2026-03-28 Q1 2026 | 2025-12-27 Q4 2025 | 2025-09-27 Q3 2025 | 2025-06-28 Q2 2025 | 2025-03-29 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-28 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.46B | $3.37B | $3.44B | $3.34B | $3.24B | $3.17B | $3.19B | $3.17B |
| Gross Margin | 31.8% | 31.8% | 28.9% | 28.7% | 29.4% | 29.6% | 29.1% | 29.3% |
| Operating Margin | 5.8% | 5.4% | 5.4% | 6.2% | 5.4% | 6.4% | 6% | 6.5% |
| Net Income | $94M | $107M | $101M | $101M | $86M | $110M | $94M | $99M |
| Diluted EPS | 0.82 | 0.92 | 0.85 | 0.84 | 0.7 | 0.88 | 0.74 | 0.78 |
| Operating Cash Flow | $242M | $-97M | $381M | $174M | $120M | $37M | $204M | $151M |
研究材料
电话会纪要摘要
暂无纪要摘要。